LGND
Ligand Pharmaceuticals Incorporated
NASDAQ: LGND · HEALTHCARE · BIOTECHNOLOGY
$224.86
-3.21% today
Updated 2026-04-29
Market cap
$2.73B
P/E ratio
36.74
P/S ratio
10.17x
EPS (TTM)
$6.12
Dividend yield
—
52W range
$99 – $247
Volume
0.2M
Ligand Pharmaceuticals Incorporated (LGND) Financial statements
SEC filings — annual and quarterly data.
Profit margin
46.40%
Operating margin
33.60%
ROE
13.50%
ROA
2.36%
Debt/equity
0.47x
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2006 | $140.96M | $-31.74M | 83.94% | -119.73% | -22.52% |
| 2007 | $12.89M | $281.69M | 100.00% | -466.69% | 2,184.64% |
| 2008 | $27.32M | $-98.11M | 100.00% | -356.13% | -359.19% |
| 2009 | $38.94M | $-1.95M | 60.88% | -25.60% | -5.00% |
| 2010 | $23.54M | $-12.52M | 100.00% | -124.50% | -53.17% |
| 2011 | $30.04M | $10.18M | 83.66% | -2.32% | 33.88% |
| 2012 | $31.39M | $-527000.00 | 88.53% | 1.83% | -1.68% |
| 2013 | $48.97M | $11.42M | 88.29% | 30.51% | 23.32% |
| 2014 | $64.54M | $12.02M | 85.84% | 30.41% | 18.63% |
| 2015 | $71.91M | $257.31M | 91.93% | 38.00% | 357.80% |
| 2016 | $108.97M | $-1.64M | 94.89% | 40.27% | -1.50% |
| 2017 | $141.10M | $12.56M | 96.20% | 48.25% | 8.90% |
| 2018 | $251.45M | $143.32M | 97.48% | 65.11% | 57.00% |
| 2019 | $120.28M | $629.30M | 90.57% | 670.99% | 523.19% |
| 2020 | $163.56M | $-2.98M | 81.40% | 22.93% | -1.82% |
| 2021 | $241.54M | $57.14M | 74.26% | 42.99% | 23.66% |
| 2022 | $196.25M | $-33.36M | 73.08% | 1.55% | -17.00% |
| 2023 | $131.31M | $52.15M | 73.31% | 9.09% | 39.72% |
| 2024 | $167.13M | $-4.03M | 93.37% | -13.53% | -2.41% |
| 2025 | $268.09M | $124.45M | 97.54% | 17.61% | 46.42% |